Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer

Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Res
Main Authors: Wright, Tricia M, Wardell, Suzanne E, Jasper, Jeff S, Stice, James P, Safi, Rachid, Nelson, Erik R, McDonnell, Donald P
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4272635/
https://ncbi.nlm.nih.gov/pubmed/25100862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-14-0195
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados